Simulation of natural convective boundary layer flow of a nanofluid past a convectively heated inclined plate in the presence of magnetic field

AbstractThis paper deals with the numerical simulation of transient magnetohydrodynamics natural convective boundary layer flow of a nanofluid over an inclined plate. In the modeling of nanofluids, dynamic effects including the Brownian motion and thermophoresis are taken into account. Numerical solutions have been computed via the Galerkin-finite element method. The effects of angle of inclination, buoyancy-ratio parameter, Brownian motion, thermophoresis and magnetic field are taken into account and controlled by non-dimensional parameters. To compute the rate of convergence and error of the computed numerical solution, the double mesh principle is used. Similarity solutions are calculated and presented graphically for non-dimensional velocity, temperature, local rate of heat and mass transfer with pertinent parameters. The modified Nusselt number decreases with increasing inclination angle, buoyancy-ratio parameter, Brownian motion and thermophoresis parameter, whereas it increases with increasing Prandtl number. Validation of the results is achieved with earlier results for forced convective flow and non-magnetic studies. Such problems have several applications in engineering and petroleum industries such as electroplating, chemical processing of heavy metals and solar water heaters. External magnetic fields play an important role in electrical power generation, inclination/acceleration sensors, fine-tuning of the final materials to industrial specification because of their controlling behaviour on the flow characteristics of nanofluids

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications.</jats:p

Differences in the mechanism of inoculation between a semi-persistent and a non-persistent aphid-transmitted plant virus

Inoculation of the semi-persistent cauliflower mosaic virus (CaMV, genus Caulimovirus) is associated with successive brief (5-10 s) intracellular stylet punctures (pd) when aphids probe in epidermal and mesophyll cells. In contrast to non-persistent viruses, there is no evidence for which of the pd subphases (II-1, II-2 and II-3) is involved in the inoculation of CaMV. Experiments were conducted using the electrical penetration graph (EPG) technique to investigate which particular subphases of the pd are associated with the inoculation of CaMV to turnip by its aphid vector Brevicoryne brassicae. In addition, the same aphid species/test plant combination was used to compare the role of the pd subphases in the inoculation of the non-persistent turnip mosaic virus (TuMV, genus Potyvirus). Inoculation of TuMV was found to be related to subphase II-1, confirming earlier results, but CaMV inoculation appeared to be related exclusively to subphase II-2 instead. The mechanism of CaMV inoculation and the possible nature of subphase II-2 are discussed in the scope of our findings

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. The greatest activity was observed in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. Futibatinib demonstrated a manageable safety profile. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%). These results formed the basis for ongoing futibatinib phase II/III trials and demonstrate the potential of genomically selected early-phase trials to help identify molecular subsets likely to benefit from targeted therapy

Constitutive basal and stimulated human small bowel contractility is enhanced in obesity

Small bowel contractility may be more prominent in obese subjects, such that there is enhanced nutrient absorption and hunger stimulation. However, there is little evidence to support this. This study examined in vitro small bowel contractility in obese patients versus non-obese patients